Type 2 & other diabetes

Evaluation of the role of atherogenic index of plasma in the reversion from Prediabetes to normoglycemia or progression to Diabetes: a multi-center retrospective cohort study

Cardiovasc DiabetolPublished Retrospective cohort study

Authors' conclusion

Our study, for the first time, reveals a negative correlation between AIP and the reversion from prediabetes to normoglycemia and validates the crucial role of AIP in the risk assessment of prediabetes progression. Based on threshold analysis, therapeutically, keeping the AIP below 0.04 was of paramount importance for individuals with prediabetes aiming for reversion to NFG; preventatively, maintaining AIP below 0.17 was vital to reduce the risk of diabetes onset for those with prediabetes.

Study context

Population
Adults with prediabetes from 32 regions across 11 cities in China (Rich Healthcare Group medical examination institutions)
Participants
15,421 adults
Exposure
Atherogenic index of plasma (AIP) and reversion to normal fasting glucose (NFG) or progression to diabetes
Outcome
Reversion from prediabetes to normal fasting glucose (NFG) or progression to diabetes
Follow-up
Median 2.9 years
Methodological detailsmulticentre
  • Multicentre

Main finding

As reported in the abstract

Reverted to NFG

6,481

42.03%

Progressed to diabetes

2,424

15.72%

AIP and progression to diabetes, HR

1.42 (1.24-1.64) (95% CI)

AIP and reversion to NFG, HR

0.89 (0.81-0.98) (95% CI)

Observational data: associations, not effects.

Further findings

Nonlinearity (restricted cubic spline (RCS)) and turning points of AIP

Turning point for reversion to NFG
0.04
Turning point for progression to diabetes
0.17
  • Nonlinear relationship

Age subgroups

AIP-associated risk of progression to diabetes relatively higher in younger populations; younger age favored reversion to NFG in relation to AIP

Original publication

Evaluation of the role of atherogenic index of plasma in the reversion from Prediabetes to normoglycemia or progression to Diabetes: a multi-center retrospective cohort study. Cardiovasc Diabetol. Published 6 January 2024. doi:10.1186/s12933-023-02108-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.